bioRxiv · Nov 16, 2026
Nicotinamide Riboside Attenuates inflammation in a mouse model of psoriasis
By Oliva A, Cayuela I, Yebra JS et al.
Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, in which IL-17-producing T cells play a central role. Nicotinamide riboside (NR), a precursor of NAD+, has recently emerged as a potential immunomodulatory intervention. Previous studies have shown that NR preferentially suppresses Th17 responsiveness in CD4+ T cells from individuals with psoriasis, but whether NR can attenuate psoriasiform inflammation in vivo remains poorly defined. Here, we investigated the effects of NR supplementation in a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation. NR treatment markedly attenuated IMQ-induced splenomegaly and reduced epidermal thickening, indicating an improvement of both systemic and cutaneous inflammatory manifestations. Flow cytometric analysis of skin infiltrates revealed a reduction in inflammatory myeloid populations, including neutrophils and inflammatory monocyte-macrophages, together with a pronounced decrease in dermal TCR {gamma}{delta} and CD4+ T cells. Consistent with these findings, CD4+ T cells isolated from IMQ-treated mice displayed increased IL-17A production following ex vivo TCR stimulation, which was significantly reduced by NR supplementation in a dose-dependent manner. IFN{gamma} and IL-4 responses were not significantly altered by NR in this setting. Furthermore, NR suppressed IL-17A production in Th17-polarized CD4+ T cells, while leaving Th1 and Th2 responses largely unaffected. Together, these findings show that NR treatment attenuates IMQ-induced psoriasiform skin inflammation in vivo and preferentially modulates IL-17A-associated CD4 T-cell responses. The accompanying reduction in dermal {gamma}{delta} T-cell numbers suggests that NR may also influence innate-like T-cell populations involved in cutaneous inflammation, providing experimental evidence for NAD+ boosting as a potential immunomodulatory strategy in psoriasis.